FDA approves weight loss drug Zepbound to treat obstructive sleep apnea - NPR
The FDA authorized Zepbound, a weight loss drug by Eli Lilly & Co., for adults with obesity and moderate to severe obstructive sleep apnea (OSA). Studies showed Zepbound reduced OSA symptoms, with significant reductions in breathing pauses compared to a placebo. The drug is used with a reduced-calorie diet and exercise.
Highlighted Terms
Related News
FDA approves weight loss drug Zepbound to treat obstructive sleep apnea - NPR
The FDA authorized Zepbound, a weight loss drug by Eli Lilly & Co., for adults with obesity and moderate to severe obstructive sleep apnea (OSA). Studies showed Zepbound reduced OSA symptoms, with significant reductions in breathing pauses compared to a placebo. The drug is used with a reduced-calorie diet and exercise.